Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:42 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 541540 | NSE: SOLARA

Solara Active Pharma Sciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹2.12Overvalued by 99.54%vs CMP ₹459.00

P/E (15.0) × ROE (0.1%) × BV (₹347.00) × DY (2.00%)

Defaults: P/E=15

₹220.30Overvalued by 52.00%vs CMP ₹459.00
MoS: -108.4% (Negative)Confidence: 43/100 (Low)Models: 2 Under, 1 Fair, 4 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹3.2126%Over (-99.3%)
Graham NumberEarnings₹34.2219%Over (-92.5%)
Net Asset ValueAssets₹284.5210%Over (-38%)
EV/EBITDAEnterprise₹545.4513%Under (+18.8%)
Earnings YieldEarnings₹1.5010%Over (-99.7%)
ROCE CapitalReturns₹602.0913%Under (+31.2%)
Revenue MultipleRevenue₹436.998%Fair (-4.8%)
Consensus (7 models)₹220.30100%Overvalued
Key Drivers: EPS CAGR 50.9% lifts DCF — verify sustainability. | ROE 0.1% is below cost of equity.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 50.9% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

40
Solara Active Pharma Sciences Ltd scores 40/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health38/100 · Weak
ROCE 6.0% WeakROE 0.1% WeakD/E 0.32 ModerateInterest Coverage 0.0x RiskyProfitable 2/5 years Inconsistent
Smart Money45/100 · Moderate
FII holding down -2.65% (6mo) SellingDII holding up 1.03% MF buyingPromoter holding at 42.0% Stable
Earnings Quality50/100 · Moderate
OPM stable around 5% Steady
Quarterly Momentum40/100 · Moderate
Revenue (4Q): -4% YoY FlatOPM: 11.0% (down 8.0% YoY) Margin pressure
Industry Rank25/100 · Weak
ROCE 6.0% vs industry 16.4% Below peersROE 0.1% vs industry 15.2% Below peers3Y sales CAGR: 0% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:42 am

Market Cap 2,023 Cr.
Current Price 459
Intrinsic Value₹220.30
High / Low 734/422
Stock P/E
Book Value 347
Dividend Yield0.00 %
ROCE6.01 %
ROE0.05 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Solara Active Pharma Sciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Solara Active Pharma Sciences Ltd 2,023 Cr. 459 734/422 3470.00 %6.01 %0.05 % 10.0
Morepen Laboratories Ltd 2,038 Cr. 37.2 70.5/33.026.7 21.80.54 %15.1 %11.8 % 2.00
Panacea Biotec Ltd 1,992 Cr. 325 582/292 1350.00 %4.57 %4.92 % 1.00
Hikal Ltd 1,972 Cr. 160 457/14678.9 96.90.88 %9.85 %7.38 % 2.00
Unichem Laboratories Ltd 2,100 Cr. 298 712/27820.0 3460.00 %6.24 %5.59 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Solara Active Pharma Sciences Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 395381352425212299363347300273319314349
Expenses 350332333388374290322286243228262279312
Operating Profit 45491938-1621042615845573537
OPM % 11%13%5%9%-76%3%12%18%19%17%18%11%11%
Other Income 752-4-62-120101610-7
Interest 24222524253131282729242122
Depreciation 28262626262525252524242426
Profit before tax 15-29-17-275-167-1388-211-10-17
Tax % 22%25%-35%0%0%53%0%0%0%0%0%0%0%
Net Profit 04-19-17-275-255-1388-211-10-17
EPS in Rs 0.090.79-4.07-3.58-57.36-53.20-3.742.222.24-0.582.91-2.79-4.82

Last Updated: March 3, 2026, 2:38 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 10:15 pm

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 5211,3871,3221,6171,2681,4441,2891,2841,255
Expenses 4641,1741,0621,2311,1881,3091,3841,0771,080
Operating Profit 5721326038681134-95206174
OPM % 11%15%20%24%6%9%-7%16%14%
Other Income 21227291622-18581
Interest 25827884759010511596
Depreciation 3483941091121111039998
Profit before tax 060115222-91-45-4881-19
Tax % -70%1%0%0%-36%-50%16%0%
Net Profit 059115221-58-22-5671-19
EPS in Rs 17.3032.0146.22-12.11-4.62-118.210.15-5.28
Dividend Payout % 0%22%5%11%0%-49%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)94.92%92.17%-126.24%62.07%-2477.27%100.18%
Change in YoY Net Profit Growth (%)0.00%-2.74%-218.42%188.31%-2539.34%2577.45%

Solara Active Pharma Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:-1%
3 Years:0%
TTM:-5%
Compounded Profit Growth
10 Years:%
5 Years:-66%
3 Years:26%
TTM:106%
Stock Price CAGR
10 Years:%
5 Years:-5%
3 Years:18%
1 Year:-9%
Return on Equity
10 Years:%
5 Years:-4%
3 Years:-11%
Last Year:0%

Last Updated: September 5, 2025, 1:31 pm

Balance Sheet

Last Updated: December 4, 2025, 2:00 am

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 252627363636364044
Reserves 7399301,0591,5531,4891,4648981,0541,210
Borrowings 6335387226211,0371,0131,012796646
Other Liabilities 425466346404383386406342393
Total Liabilities 1,8211,9602,1532,6142,9452,8992,3512,2322,293
Fixed Assets 1,0861,2181,3971,3821,3561,3641,2681,1931,232
CWIP 71404088239238256280230
Investments 100002222
Other Assets 6637017161,1441,3501,295825757829
Total Assets 1,8211,9602,1532,6142,9452,8992,3512,2322,293

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 49166242155-242156109213
Cash from Investing Activity + -85-113-359-106-243-81-4-37
Cash from Financing Activity + 68-239792334-113-106-180
Net Cash Flow 3130-20142-151-38-0-4
Free Cash Flow 14108-25-16-4514669173
CFO/OP 92%85%103%49%-277%106%-113%104%

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-576.00-325.00-462.00-235.0080.00133.00-96.00-590.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 18476631091411369993
Inventory Days 252111170149321258163185
Days Payable 420127132156154142142145
Cash Conversion Cycle 1660101102308252120133
Working Capital Days -124-22-32163720-128-62
ROCE %10%12%15%-0%2%-9%6%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 40.98%39.31%37.19%30.49%30.49%37.27%37.27%37.23%37.94%42.01%42.01%42.00%
FIIs 19.30%18.71%17.86%16.62%15.80%14.00%14.25%14.67%14.63%14.25%13.58%11.98%
DIIs 2.75%1.75%1.79%1.75%2.97%2.83%3.37%3.19%2.61%2.62%2.69%3.64%
Public 36.95%40.22%43.16%51.14%50.73%45.89%45.11%44.92%44.82%41.10%41.71%42.37%
No. of Shareholders 76,32575,41774,47372,91873,91277,17071,88283,14875,79174,33472,47971,890

Shareholding Pattern Chart

No. of Shareholders

Solara Active Pharma Sciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Aditya Birla Sun Life Flexi Cap Fund 420,000 0.08 19.41420,0002025-04-22 17:25:200%
Aditya Birla Sun Life Manufacturing Equity Fund 146,107 0.61 6.7565,0002025-08-29 00:02:49124.78%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 0.14-157.62-6.16-16.1869.00
Diluted EPS (Rs.) 0.14-157.62-6.16-16.1864.53
Cash EPS (Rs.) 24.79-128.7924.7015.0191.87
Book Value[Excl.RevalReserv]/Share (Rs.) 271.86260.16417.35424.22443.42
Book Value[Incl.RevalReserv]/Share (Rs.) 271.86260.16417.35424.22443.42
Revenue From Operations / Share (Rs.) 318.95358.03401.06352.32450.13
PBDIT / Share (Rs.) 53.32-24.9543.4527.77115.43
PBIT / Share (Rs.) 28.66-53.6512.57-3.4285.18
PBT / Share (Rs.) 0.13-135.67-12.45-25.3161.66
Net Profit / Share (Rs.) 0.13-157.49-6.18-16.1961.62
NP After MI And SOA / Share (Rs.) 0.13-157.61-6.16-16.1561.64
PBDIT Margin (%) 16.71-6.9610.837.8825.64
PBIT Margin (%) 8.98-14.983.13-0.9718.92
PBT Margin (%) 0.04-37.89-3.10-7.1813.69
Net Profit Margin (%) 0.04-43.98-1.54-4.5913.68
NP After MI And SOA Margin (%) 0.04-44.02-1.53-4.5813.69
Return on Networth / Equity (%) 0.04-60.75-1.47-3.8113.93
Return on Capital Employeed (%) 8.95-17.422.51-0.6516.76
Return On Assets (%) 0.02-24.13-0.76-1.968.47
Long Term Debt / Equity (X) 0.100.110.150.180.09
Total Debt / Equity (X) 0.701.070.660.670.32
Asset Turnover Ratio (%) 0.560.490.490.450.67
Current Ratio (X) 0.770.641.081.161.34
Quick Ratio (X) 0.430.350.570.610.96
Inventory Turnover Ratio (X) 3.791.661.371.972.38
Dividend Payout Ratio (NP) (%) 0.000.000.00-18.538.90
Dividend Payout Ratio (CP) (%) 0.000.000.0019.905.97
Earning Retention Ratio (%) 0.000.000.00118.5391.10
Cash Earning Retention Ratio (%) 0.000.000.0080.1094.03
Interest Coverage Ratio (X) 1.87-0.851.741.334.91
Interest Coverage Ratio (Post Tax) (X) 1.00-2.580.750.273.62
Enterprise Value (Cr.) 2838.242334.272176.743374.175329.56
EV / Net Operating Revenue (X) 2.211.811.512.663.30
EV / EBITDA (X) 13.23-25.9913.9233.7412.85
MarketCap / Net Operating Revenue (X) 1.611.040.811.893.10
Retention Ratios (%) 0.000.000.00118.5391.09
Price / BV (X) 1.891.440.781.573.15
Price / Net Operating Revenue (X) 1.611.040.811.893.10
EarningsYield 0.00-0.42-0.01-0.020.04

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Solara Active Pharma Sciences Ltd. is a Public Limited Listed company incorporated on 23/02/2017 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH2017PLC291636 and registration number is 291636. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 1283.76 Cr. and Equity Capital is Rs. 40.25 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals�Cyber One�, Unit No. 902, Plot No. 4 & 6, Sector 30A, New Mumbai Maharashtra 400703Contact not found
Management
NamePosition Held
Mr. R RamakrishnanChairperson & Independent Director
Mr. Sandeep Shashikantha RaoManaging Director & CEO
Mr. Mohan MuthunarayananWhole Time Director & COO
Mr. Manish GuptaNon Executive Director
Mr. Kartheek Chintalapati RajuNon Executive Director
Mr. Arun Kumar PillaiNon Executive Director
Dr. Kausalya SanthanamIndependent Director
Mr. Rajiv Vijay NabarIndependent Director
Mr. Rajendra Kumar SrivastavaIndependent Director

FAQ

What is the intrinsic value of Solara Active Pharma Sciences Ltd and is it undervalued?

As of 11 April 2026, Solara Active Pharma Sciences Ltd's intrinsic value is ₹220.30, which is 52.00% lower than the current market price of ₹459.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (0.05 %), book value (₹347), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Solara Active Pharma Sciences Ltd?

Solara Active Pharma Sciences Ltd is trading at ₹459.00 as of 11 April 2026, with a FY2026-2027 high of ₹734 and low of ₹422. The stock is currently near its 52-week low. Market cap stands at ₹2,023 Cr..

How does Solara Active Pharma Sciences Ltd's P/E ratio compare to its industry?

Solara Active Pharma Sciences Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Solara Active Pharma Sciences Ltd financially healthy?

Key indicators for Solara Active Pharma Sciences Ltd: ROCE of 6.01 % is on the lower side compared to the industry average of 16.35%; ROE of 0.05 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Solara Active Pharma Sciences Ltd profitable and how is the profit trend?

Solara Active Pharma Sciences Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹1,284 Cr. Compared to ₹-58 Cr in Mar 2022, the net profit shows an improving trend.

Does Solara Active Pharma Sciences Ltd pay dividends?

Solara Active Pharma Sciences Ltd has a dividend yield of 0.00 % at the current price of ₹459.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Solara Active Pharma Sciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports